Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases

Thumbnail Image

Files

J of Extracellular Vesicle - 2023 - Li - Current challenges and future directions for engineering extracellular vesicles.pdf (1.14 MB)
J of Extracellular Vesicle - 2023 - - Correction to Current challenges and future directions for engineering.pdf (51.6 KB)

Links to Files

https://isevjournals.onlinelibrary.wiley.com/doi/full/10.1002/jev2.12305

Permanent Link

https://doi.org/10.1002/jev2.12305
 http://hdl.handle.net/11603/27021

Collections

UMBC Biological Sciences Department
UMBC Faculty Collection

Author/Creator

Author/Creator ORCID

https://orcid.org/0000-0001-7603-9276

Date

2023-02-12

Type of Work

journal articles
Text

Department

Program

Citation of Original Publication

Li, G., Chen, T., Dahlman, J., Eniola-Adefeso, L., Ghiran, I. C., Kurre, P., Lam, W. A., Lang, J. K., Marbán, E., Martín, P., Momma, S., Moos, M., Nelson, D. J., Raffai, R. L., Ren, X., Sluijter, J. P. G., Stott, S. L., Vunjak-Novakovic, G., Walker, N. D., … Sundd, P. (2023). Current challenges and future directions for engineering extracellular vesicles for heart, lung, blood and sleep diseases. Journal of Extracellular Vesicles, 12, e12305. https://doi.org/10.1002/jev2.12305

Rights

This work was written as part of one of the author's official duties as an Employee of the United States Government and is therefore a work of the United States Government. In accordance with 17 U.S.C. 105, no copyright protection is available for such works under U.S. Law.
Public Domain Mark 1.0

Subjects

Abstract

Extracellular vesicles (EVs) carry diverse bioactive components including nucleicacids, proteins, lipids and metabolites that play versatile roles in intercellular andinterorgan communication. The capability to modulate their stability, tissue-specifictargeting and cargo render EVs as promising nanotherapeutics for treating heart,lung, blood and sleep (HLBS) diseases. However, current limitations in large-scalemanufacturing of therapeutic-grade EVs, and knowledge gaps in EV biogenesis andheterogeneity pose significant challenges in their clinical application as diagnosticsor therapeutics for HLBS diseases. To address these challenges, a strategic workshopwith multidisciplinary experts in EV biology and U.S. Food and Drug Administration(USFDA) officials was convened by the National Heart, Lung and Blood Institute. Thepresentations and discussions were focused on summarizing the current state of sci-ence and technology for engineering therapeutic EVs for HLBS diseases, identifyingcritical knowledge gaps and regulatory challenges and suggesting potential solutionsto promulgate translation of therapeutic EVs to the clinic. Benchmarks to meet thecritical quality attributes set by the USFDA for other cell-based therapeutics werediscussed. Development of novel strategies and approaches for scaling-up EV pro-duction and the quality control/quality analysis (QC/QA) of EV-based therapeuticswere recognized as the necessary milestones for future investigations.